Global Anti-Obesity Prescription Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027
Request Covid 19 Impact
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Global Anti-Obesity Prescription Drugs Market Overview :
“The global anti-obesity prescription drugs Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031.”
The global anti-obesity prescription drugs market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global anti-obesity prescription drugs market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027.
The report offers insightful and detailed information regarding the various key players operating in the global anti-obesity prescription drugs market, their financials, supply chain trends, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global anti-obesity prescription drugs market report has been segmented on the basis of mechanism of action, target site, drug type, therapy, end-user and region.
Obesity is a medical condition in which excess body fat get saturated into human body to the level that it may have adverse impact on health. Obesity results from a combination of causes and individual factors such as behavior and genetics. Behaviors can include dietary patterns, limited physical activity, medication use, and other exposures.
Body Mass Index (BMI) is a method used for measuring obesity among people. The body mass index (BMI) is a statistical measurement derived by using basic variables such as height and weight of a person. World Health Organization (WHO) defines obesity for adult who have a BMI greater than or equal to 30 and children, ages 5-19 years, at or above the 85th percentile on the CDC growth charts. Anti-obesity drugs contain certain pharmacological ingredient intended to reduce or control weight.
Regulation of body weight is controlled by the brain cells which uses a variety of neuropeptides and transmitters, and are responsive to endocrine and metabolic signals. Targeting these cells with novel pharmaceutical drugs is the basic way of controlling obesity. Medically anti-obesity drugs are prescribed only in cases of morbid obesity, where weight loss is life-saving. An anti-obesity drug therapy is prescribed for a maximum of 12 weeks and then weight loss is measured.
Most of the time, the drug treatment is stopped when the obese patients do not reach a 5% weight reduction even after 12 weeks of drug therapy. Lifestyle reform (diet, physical activity, behavior change), medications, and bariatric surgery are the three primary treatment of obesity.
Increased uptake of food products with high level of cholesterol leads to obesity which in turn is expected to drive the consumption of anti-obesity drug. Limited physical activities and hereditary diseases are some of the other factors driving the demand of anti-obesity prescription drug market. Changing lifestyle, sharp growth in package food consumption of diabetic and psychotropic drugs are some other factors that are expected to drive the growth of global anti-obesity prescription drug market.
High cost involved in research and development and manufacturing process of anti-obesity prescription drugs, rise in herbal weight loss products, side effects of anti-obesity drugs, and rising acceptances of alternative options such as gymnasiums, fitness spas, therapies to reduce obesity, increasing patient compliance for surgical procedures, high change in diet plan are the factors that are expected to hamper the demand of anti-obesity drug market. In addition to rise in organic and fat-free products are expected to hinder the growth of anti-prescription drug market to a certain extent.
New drug delivery method of skin patch that allows anti-obesity drugs to be administered with a lowing threat of side effects, nano sized soy phytosome-based thermogel as topical anti-obesity formulation, Herbal supplements, Gene mutation related to obesity is the new treatment trend in anti-obesity drug market.
The global anti-obesity prescription drug market report has been segmented on the basis of mechanism of action, target site, drug type, therapy, end-user and region. On the basis of region, the global anti-obesity prescription drug market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Global Anti-Obesity Prescription Drugs Market Segmentation:
Global anti-obesity prescription drugs market segmentation by mechanism of action:
- Incretin mimetics/GLP-1 agonists
- Lipase inhibitors
- Serotonin receptor agonists
- Sympathomimetic-GABA receptor agonists
- Others (human Glucagon-like peptide-1 analog, inhibitors of dopamine & noradrenalin etc.)
Global anti-obesity prescription drugs market segmentation by target site:
- Peripherally acting anti-obesity drugs
- Centrally acting anti-obesity drugs
Global anti-obesity prescription drugs market segmentation, by therapy:
Global anti-obesity prescription drugs market segmentation, by distribution channel:
Global anti-obesity prescription drugs market segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Bristol-Myers Squibb Co.
- Takeda Pharmaceutical Company Ltd.
- Eisai Co., Ltd.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Shionogi USA, Inc.
- Vivus Inc.
- Zafgen Inc.
- Norgine BV
- Boehringer Ingelheim GmbH.
Request for TOC
Don't just take our word. We are trusted by these great companies!